作者: Jacqueline Saw , Mathieu Lempereur
DOI: 10.1016/J.JCIN.2014.05.026
关键词:
摘要: Percutaneous left atrial appendage closure technology for stroke prevention in patients with fibrillation has significantly advanced the past 2 decades. Several devices are under clinical investigation, and a few have already received Conformite Europeene (CE)-mark approval available many countries. The WATCHMAN device (Boston Scientific, Natick, Massachusetts) most supportive data is evaluation by U.S. Food Drug Administration warfarin-eligible patients. Amplatzer Cardiac Plug (St. Jude Medical, Plymouth, Minnesota) large real-world experience over 5 years, randomized trial comparing anticipated near future. Lariat procedure (SentreHEART Inc., Redwood City, California) also gained interest lately, but early studies were concerning high rates of serious pericardial effusion major bleeding. current predominantly involves who not long-term anticoagulation candidates or perceived to bleeding risks. This pattern practice expected change when approves paper reviews depth procedural techniques, safety, outcomes leading devices.